Aurinia Pharmaceuticals Q4 2023 GAAP EPS $(0.19) Misses $(0.16) Estimate, Sales $45.10M Beat $44.33M Estimate
Portfolio Pulse from Benzinga Newsdesk
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported Q4 2023 GAAP EPS of $(0.19), missing the $(0.16) estimate, but sales of $45.10M exceeded the $44.33M estimate, marking a 58.61% increase from the previous year.
February 15, 2024 | 11:00 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Aurinia Pharmaceuticals reported a Q4 2023 GAAP EPS of $(0.19), missing estimates, but sales of $45.10M exceeded expectations, showing a significant year-over-year growth.
While the EPS miss might concern some investors, the significant sales beat and year-over-year growth could offset negative sentiment. The mixed results present a neutral short-term outlook as the sales growth indicates strong demand for Aurinia's products, but the EPS miss may raise questions about profitability.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100